Joshua S Waitzman1, Jennie Lin1,2,3. 1. Division of Nephrology and Hypertension. 2. Feinberg Cardiovascular and Renal Research Institute, Northwestern University Feinberg School of Medicine. 3. Jesse Brown Veterans Affairs Medical Center, Chicago, Illinois, USA.
Abstract
PURPOSE OF REVIEW: APOL1 nephropathy risk variants drive most of the excess risk of chronic kidney disease (CKD) seen in African Americans, but whether the same risk variants account for excess cardiovascular risk remains unclear. This mini-review highlights the controversies in the APOL1 cardiovascular field. RECENT FINDINGS: In the past 10 years, our understanding of how APOL1 risk variants contribute to renal cytotoxicity has increased. Some of the proposed mechanisms for kidney disease are biologically plausible for cells and tissues relevant to cardiovascular disease (CVD), but cardiovascular studies published since 2014 have reported conflicting results regarding APOL1 risk variant association with cardiovascular outcomes. In the past year, several studies have also contributed conflicting results from different types of study populations. SUMMARY: Heterogeneity in study population and study design has led to differing reports on the role of APOL1 nephropathy risk variants in CVD. Without consistently validated associations between these risk variants and CVD, mechanistic studies for APOL1's role in cardiovascular biology lag behind.
PURPOSE OF REVIEW: APOL1nephropathy risk variants drive most of the excess risk of chronic kidney disease (CKD) seen in African Americans, but whether the same risk variants account for excess cardiovascular risk remains unclear. This mini-review highlights the controversies in the APOL1 cardiovascular field. RECENT FINDINGS: In the past 10 years, our understanding of how APOL1 risk variants contribute to renal cytotoxicity has increased. Some of the proposed mechanisms for kidney disease are biologically plausible for cells and tissues relevant to cardiovascular disease (CVD), but cardiovascular studies published since 2014 have reported conflicting results regarding APOL1 risk variant association with cardiovascular outcomes. In the past year, several studies have also contributed conflicting results from different types of study populations. SUMMARY: Heterogeneity in study population and study design has led to differing reports on the role of APOL1nephropathy risk variants in CVD. Without consistently validated associations between these risk variants and CVD, mechanistic studies for APOL1's role in cardiovascular biology lag behind.
Authors: Carl D Langefeld; Mary E Comeau; Maggie C Y Ng; Meijian Guan; Latchezar Dimitrov; Poorva Mudgal; Mitzie H Spainhour; Bruce A Julian; Jeffrey C Edberg; Jennifer A Croker; Jasmin Divers; Pamela J Hicks; Donald W Bowden; Gary C Chan; Lijun Ma; Nicholette D Palmer; Robert P Kimberly; Barry I Freedman Journal: Kidney Int Date: 2018-06-07 Impact factor: 10.612
Authors: Pazit Beckerman; Jing Bi-Karchin; Ae Seo Deok Park; Chengxiang Qiu; Patrick D Dummer; Irfana Soomro; Carine M Boustany-Kari; Steven S Pullen; Jeffrey H Miner; Chien-An A Hu; Tibor Rohacs; Kazunori Inoue; Shuta Ishibe; Moin A Saleem; Matthew B Palmer; Ana Maria Cuervo; Jeffrey B Kopp; Katalin Susztak Journal: Nat Med Date: 2017-02-20 Impact factor: 53.440
Authors: H V Xong; L Vanhamme; M Chamekh; C E Chimfwembe; J Van Den Abbeele; A Pays; N Van Meirvenne; R Hamers; P De Baetselier; E Pays Journal: Cell Date: 1998-12-11 Impact factor: 41.582
Authors: Jia-Yue Zhang; Minxian Wang; Lei Tian; Giulio Genovese; Paul Yan; James G Wilson; Ravi Thadhani; Amy K Mottl; Gerald B Appel; Alexander G Bick; Matthew G Sampson; Seth L Alper; David J Friedman; Martin R Pollak Journal: Proc Natl Acad Sci U S A Date: 2018-03-12 Impact factor: 11.205
Authors: Mary E Haas; Krishna G Aragam; Connor A Emdin; Alexander G Bick; Gibran Hemani; George Davey Smith; Sekar Kathiresan Journal: Am J Hum Genet Date: 2018-09-13 Impact factor: 11.025
Authors: Orlando M Gutiérrez; Marguerite R Irvin; Ninad S Chaudhary; Mary Cushman; Neil A Zakai; Victor A David; Sophie Limou; Nathalie Pamir; Alex P Reiner; Rakhi P Naik; Michele M Sale; Monika M Safford; Hyacinth I Hyacinth; Suzanne E Judd; Jeffrey B Kopp; Cheryl A Winkler Journal: Circ Genom Precis Med Date: 2018-06